Headlines
-
Sigma records 41% EBIT growth in FY25
Wednesday | Aug 27 2025SIGMA recorded normalised EBIT growth of 41% and statutory net profit after tax of $529.9 million in its first post-merger end-of-year results, according to an ASX statement this morning.
-
Painkiller link with AMR
Wednesday | Aug 27 2025IN THE first study of its kind, Australian researchers have discovered that ibuprofen and paracetamol could be driving antimicrobial resistance (AMR) when used in conjunction with broad-spectrum antibiotic ciprofloxacin.
-
APC public consultation EOI
Tuesday | Aug 26 2025THE Australian Pharmacy Council (APC) has announced that the expression of interest (EOI) to participate in the public consultation forums for the Pharmacist Capability Framework is now open.
-
Board guidelines consultation
Tuesday | Aug 26 2025THE Pharmacy Board of Australia has released draft Guidelines for pharmacists on the safe provision of pharmacy services including medicines and advice for public consultation.
-
Risks posed by AI in healthcare
Tuesday | Aug 26 2025MEDTECH consultant Ivor Campbell shares insights into some of the issues around artificial intelligence (AI) in healthcare.
-
PSA welcomes new ECP CSI leaders
Monday | Aug 25 2025THE Pharmaceutical Society of Australia (PSA) has introduced the new leaders for the Early Career Pharmacist (ECP) Community of Specialty Interest (CSI), a group that will inspire and empower Australia's next generation of pharmacists.
-
PBAC outcomes disappoint
Monday | Aug 25 2025THE Pharmaceutical Benefits Advisory Committee (PBAC) has knocked back Lilly's application for PBS listing of its high-profile dementia drug Kisunla (donanemab) (PD 22 May) at the Jul 2025 meeting.
-
Ozempic reduces cancer risk
Friday | Aug 22 2025PEOPLE with obesity who take glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reduced risk of cancer compared to those not using those medications, according to US research published today in JAMA Oncology.
-
No business like Snow Business
Friday | Aug 22 2025PHARMACISTS from across Australia recently came together for the Pharmacy Snow Business Conference at Mt Buller, sharing a passion for skiing alongside their commitment to professional development.
-
Pharmx delivers strong FY25
Thursday | Aug 21 2025PHARMX Technologies yesterday announced strong results for the financial year ending 30 Jun 2025, with total revenues of $7.5 million, up 13% on the previous corresponding period.
